1 / 6

High incidence of asymptomatic AF

High incidence of asymptomatic AF. 110 patients with history of paroxysmal/persistent AF but in sinus rhythm at baseline. All patients received antiarrhythmic drug therapy. AF detected by implanted monitoring pacemaker. 100. 80. P < 0.0001. 60. Patients. 40.

aline-baldwin
Download Presentation

High incidence of asymptomatic AF

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. High incidence of asymptomatic AF 110 patients with history of paroxysmal/persistent AF but in sinusrhythm at baseline. All patients received antiarrhythmic drug therapy AF detected by implanted monitoring pacemaker 100 80 P < 0.0001 60 Patients 40 AF detected by ECG at follow-up (FU) visit 20 0 Baseline FU1 FU2 FU3 FU4 FU5 FU6 FU7 FU8 FU9 FU10 n 110 110 110 110 85 73 60 48 39 25 15 Israel CW et al. J Am Coll Cardiol. 2004:43:47-52.

  2. High incidence of asymptomatic AF: Clinical implications “The implications for treatment are clear, namely that apparent freedom from AF does not, per se, obviate the need for oral anticoagulation.” Kaufman ES, Waldo AL. J Am Coll Cardiol. 2004;43:53-4.

  3. INR Odds ratio* (3-mos mortality) <2.0 2.0–3.0 >3.0 1.9 2.7 5.5 Warfarin increases hemorrhagic stroke mortality Lobar ICH Deep hemispheric ICH 60 60 57.6 40 40 44.2 %Patients 28.6 20 20 22.5 0 0 Nowarfarin Warfarin Nowarfarin Warfarin ICH = intracerebral hemorrhage *Relative to no warfarin; P < 0.01 for trend across INR categories Rosand J et al. Arch Intern Med. 2004;164:880-4.

  4. Trials of emerging antithrombotic therapiesfor stroke prevention in AF Trial Treatment Status AMADEUS Idraparinux* vs warfarin Ongoing ACTIVE Clopidogrel + aspirin Ongoingvs warfarin (ACTIVE W) or vs aspirin (ACTIVE A) SPORTIF III/V Ximelagatran vs warfarin Completed Hankey GJ et al. Stroke. 2004;35:389-91. *Administered sc 1/week

  5. SPORTIF III and V pooled results: Primary outcome Ximelagatran better Warfarin better –0.66 P = 0.10 SPORTIF III +0.45 P = 0.13 SPORTIF V –0.03 Pooled P = 0.94 Noninferiority -4 -3 -2 -1 0 1 2 3 4 Difference in absolute event rates (ximelagatran – warfarin) Stroke Prevention using an ORal ThrombinInhibitor in patients with atrial Fibrillation Halperin JL. AHA Scientific Sessions 2003; Orlando, Fla.

  6. SPORTIF III and V pooled results: Net clinical benefit On-treatment analysis Warfarin Ximelagatran Primary events + major bleeding + death 10 RRR = 26%P = 0.019 RRR = 7%P = 0.527 RRR = 16%P = 0.038 8 Eventrate(%/year) 6 6.1 6.3 6.2 5.8 5.2 4 4.6 2 0 SPORTIF III SPORTIF V Pooled RRR = relative risk reduction Stroke Prevention using an ORal ThrombinInhibitor in patients with atrial Fibrillation Halperin JL. AHA Scientific Sessions 2003; Orlando, Fla.

More Related